Clene Inc. (NASDAQ: CLNN), a biopharmaceutical company at the forefront of developing treatments for neurodegenerative diseases, has announced its Q2 2025 financial results, revealing a cash runway extending into Q1 2026. This financial stability supports the company's ongoing efforts to advance its lead candidate, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). Clene plans to engage with the FDA this quarter to discuss survival data from its studies and is preparing to analyze neurofilament light biomarker data from the NIH-sponsored Expanded Access Program, with results anticipated in Q4 2025.
The company's strategic focus is on compiling the necessary data to support a New Drug Application (NDA) submission under the FDA's accelerated approval pathway by the end of 2025. This milestone represents a critical step forward in bringing a potentially life-changing therapy to individuals suffering from ALS, a debilitating neurodegenerative disease with limited treatment options. The significance of CNM-Au8 lies in its novel mechanism of action, which aims to improve mitochondrial health and neuronal function, offering hope for not only ALS patients but also those with other neurodegenerative conditions.
For more detailed information on Clene's Q2 2025 results and its progress toward the NDA submission for CNM-Au8, visit https://ibn.fm/qTCmZ. The company's dedication to addressing unmet medical needs in neurodegenerative diseases underscores the importance of this development for patients, healthcare providers, and the biopharmaceutical industry at large.
